A recent study has shown that blocking of the IL-6 receptor (IL-6R) or TGF-β in tumor-bearing mice, decreases both monocytic and granulocytic MDSC subsets, alongside a reduction in tumor growth and improvement in T-cell function (Sumida et al., 2012). The gene discussed is IL6R; the disease is neoplasm.